UPDATE: Neos Paragraph IV From Teva Shows Allegations '3 U.S. patents listed in the FDA's Orange Book for Cotempla, 1 with an expiration date in Apr. '26, 2 with expiration dates in June 2032, will not be  infringed by Teva's proposed product'